C-reactive Protein Levels and Risk of Dementia-Observational and Genetic Studies of 111,242 Individuals from the General Population

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2022 Feb 3

PMID 35112776

Authors

Sharif H Hegazy

Jesper Qvist Thomassen

Ida Juul Rasmussen

Borge G Nordestgaard

Anne Tybjaerg-Hansen

Ruth Frikke-Schmidt

Affiliations

Soon will be listed here.

Abstract

Introduction: Increased plasma levels of C-reactive protein (CRP) in midlife are associated with increased risk of Alzheimer's disease (AD), whereas in older age the opposite association is observed. Whether genetically determined CRP is associated with AD remains unclear.

Methods: A total of 111,242 White individuals from the Copenhagen General Population Study and the Copenhagen City Heart Study were included. Plasma levels of CRP and four regulatory genetic variants in the CRP gene were determined.

Results: For CRP percentile group 1 to 5 (lowest plasma CRP) versus the 50 to 75 group (reference), the hazard ratio for AD was 1.69 (95% confidence interval 1.29-2.16). Genetically low CRP was associated with increased risk of AD in individuals with body mass index ≤25 kg/m (P = 4 × 10 ).

Discussion: Low plasma levels of CRP at baseline were associated with high risk of AD in individuals from the general population. These observational findings were supported by genetic studies.

Citing Articles

Neuropathology-based approach reveals novel Alzheimer's Disease genes and highlights female-specific pathways and causal links to disrupted lipid metabolism: insights into a vicious cycle.

Jin Y, Topaloudi A, Shekhar S, Chen G, Scott A, Colon B Acta Neuropathol Commun. 2025; 13(1):1.

PMID: 39755674 PMC: 11699708. DOI: 10.1186/s40478-024-01909-6.

Genetically proxied IL-6 signaling and risk of Alzheimer's disease and lobar intracerebral hemorrhage: A drug target Mendelian randomization study.

Myserlis E, Ray A, Anderson C, Georgakis M Alzheimers Dement (N Y). 2024; 10(3):e70000.

PMID: 39206334 PMC: 11349601. DOI: 10.1002/trc2.70000.

"Let's talk about sex, inflammaging, and cognition, baby": A meta-analysis and meta-regression of 106 case-control studies on mild cognitive impairment and Alzheimer's disease.

Childs R, Karamacoska D, Lim C, Steiner-Lim G Brain Behav Immun Health. 2024; 40:100819.

PMID: 39161876 PMC: 11331696. DOI: 10.1016/j.bbih.2024.100819.

The mediating role of systemic inflammation and moderating role of racialization in disparities in incident dementia.

Tejera C, Ware E, Hicken M, Kobayashi L, Wang H, Blostein F Commun Med (Lond). 2024; 4(1):142.

PMID: 39003383 PMC: 11246521. DOI: 10.1038/s43856-024-00569-w.

The association between religious beliefs and values with inflammation among Middle-age and older adults.

Britt K, Boateng A, Sebu J, Oh H, Lekwauwa R, Massimo L Aging Ment Health. 2024; 28(10):1343-1350.

PMID: 38553253 PMC: 11390335. DOI: 10.1080/13607863.2024.2335390.

References

Lambert J, Ibrahim-Verbaas C, Harold D, Naj A, Sims R, Bellenguez C . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013; 45(12):1452-8. PMC: 3896259. DOI: 10.1038/ng.2802. View

Rasmussen K, Tybjaerg-Hansen A, Nordestgaard B, Frikke-Schmidt R . Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort. Eur Heart J. 2019; 40(33):2813-2824. PMC: 6735871. DOI: 10.1093/eurheartj/ehz402. View

Hegazy S, Thomassen J, Rasmussen I, Nordestgaard B, Tybjaerg-Hansen A, Frikke-Schmidt R . C-reactive protein levels and risk of dementia-Observational and genetic studies of 111,242 individuals from the general population. Alzheimers Dement. 2022; 18(11):2262-2271. PMC: 9790296. DOI: 10.1002/alz.12568. View

Tanigaki K, Sundgren N, Khera A, Vongpatanasin W, Mineo C, Shaul P . Fcγ receptors and ligands and cardiovascular disease. Circ Res. 2015; 116(2):368-84. PMC: 4331353. DOI: 10.1161/CIRCRESAHA.116.302795. View

Prince M, Ali G, Guerchet M, Prina A, Albanese E, Wu Y . Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016; 8(1):23. PMC: 4967299. DOI: 10.1186/s13195-016-0188-8. View

Gong C, Wei D, Wang Y, Ma J, Yuan C, Zhang W . A Meta-Analysis of C-Reactive Protein in Patients With Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2015; 31(3):194-200. PMC: 10852780. DOI: 10.1177/1533317515602087. View

Ligthart S, Vaez A, Vosa U, Stathopoulou M, de Vries P, Prins B . Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. Am J Hum Genet. 2018; 103(5):691-706. PMC: 6218410. DOI: 10.1016/j.ajhg.2018.09.009. View

Brosseron F, Traschutz A, Widmann C, Kummer M, Tacik P, Santarelli F . Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1):25. PMC: 5828084. DOI: 10.1186/s13195-018-0353-3. View

Yin C, Ackermann S, Ma Z, Mohanta S, Zhang C, Li Y . ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat Med. 2019; 25(3):496-506. PMC: 6420126. DOI: 10.1038/s41591-018-0336-8. View

10.

Lawlor D, Harbord R, Sterne J, Timpson N, Davey Smith G . Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2007; 27(8):1133-63. DOI: 10.1002/sim.3034. View

11.

Martiskainen H, Takalo M, Solomon A, Stancakova A, Marttinen M, Natunen T . Decreased plasma C-reactive protein levels in 4 allele carriers. Ann Clin Transl Neurol. 2018; 5(10):1229-1240. PMC: 6186931. DOI: 10.1002/acn3.639. View

12.

Chasman D, Kozlowski P, Zee R, Kwiatkowski D, Ridker P . Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun. 2006; 7(3):211-9. DOI: 10.1038/sj.gene.6364289. View

13.

Duong T, Nikolaeva M, Acton P . C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Brain Res. 1997; 749(1):152-6. DOI: 10.1016/s0006-8993(96)01359-5. View

14.

Tan Z, Beiser A, Vasan R, Roubenoff R, Dinarello C, Harris T . Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 2007; 68(22):1902-8. DOI: 10.1212/01.wnl.0000263217.36439.da. View

15.

Satizabal C, Beiser A, Chouraki V, Chene G, Dufouil C, Seshadri S . Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med. 2016; 374(6):523-32. PMC: 4943081. DOI: 10.1056/NEJMoa1504327. View

16.

Kathiresan S, Larson M, Vasan R, Guo C, Gona P, Keaney Jr J . Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation. 2006; 113(11):1415-23. DOI: 10.1161/CIRCULATIONAHA.105.591271. View

17.

Iwamoto N, Nishiyama E, Ohwada J, Arai H . Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett. 1994; 177(1-2):23-6. DOI: 10.1016/0304-3940(94)90035-3. View

18.

Allin K, Nordestgaard B, Zacho J, Tybjaerg-Hansen A, Bojesen S . C-reactive protein and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst. 2010; 102(3):202-6. DOI: 10.1093/jnci/djp459. View

19.

Zacho J, Tybjaerg-Hansen A, Skov Jensen J, Grande P, Sillesen H, Nordestgaard B . Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008; 359(18):1897-908. DOI: 10.1056/NEJMoa0707402. View

20.

Coccaro E, Lee R, Coussons-Read M . Cerebrospinal fluid and plasma C-reactive protein and aggression in personality-disordered subjects: a pilot study. J Neural Transm (Vienna). 2014; 122(2):321-6. PMC: 4898482. DOI: 10.1007/s00702-014-1263-6. View